Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1986 Sep;61(9):827–829. doi: 10.1136/adc.61.9.827

Pharmacological manipulation of the ductus arteriosus.

E D Silove
PMCID: PMC1778015  PMID: 3767410

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Coceani F., Olley P. M., Bodach E. Lamb ductus arteriosus: effect of prostaglandin synthesis inhibitors on the muscle tone and the response to prostaglandin E2. Prostaglandins. 1975 Feb;9(2):299–308. doi: 10.1016/0090-6980(75)90034-9. [DOI] [PubMed] [Google Scholar]
  2. Elliott R. B., Starling M. B., Neutze J. M. Medical manipulation of the ductus arteriosus. Lancet. 1975 Jan 18;1(7899):140–142. doi: 10.1016/s0140-6736(75)91432-4. [DOI] [PubMed] [Google Scholar]
  3. Freed M. D., Heymann M. A., Lewis A. B., Roehl S. L., Kensey R. C. Prostaglandin E1 infants with ductus arteriosus-dependent congenital heart disease. Circulation. 1981 Nov;64(5):899–905. doi: 10.1161/01.cir.64.5.899. [DOI] [PubMed] [Google Scholar]
  4. Gersony W. M., Peckham G. J., Ellison R. C., Miettinen O. S., Nadas A. S. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr. 1983 Jun;102(6):895–906. doi: 10.1016/s0022-3476(83)80022-5. [DOI] [PubMed] [Google Scholar]
  5. Heymann M. A., Berman W., Jr, Rudolph A. M., Whitman V. Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities. Circulation. 1979 Jan;59(1):169–173. doi: 10.1161/01.cir.59.1.169. [DOI] [PubMed] [Google Scholar]
  6. Lewis A. B., Freed M. D., Heymann M. A., Roehl S. L., Kensey R. C. Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease. Circulation. 1981 Nov;64(5):893–898. doi: 10.1161/01.cir.64.5.893. [DOI] [PubMed] [Google Scholar]
  7. Neutze J. M., Starling M. B., Elliott R. B., Barratt-Boyes B. G. Palliation of cyanotic congenital heart disease in infancy with E-type prostaglandins. Circulation. 1977 Feb;55(2):238–241. doi: 10.1161/01.cir.55.2.238. [DOI] [PubMed] [Google Scholar]
  8. Olley P. M., Coceani F., Bodach E. E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations. Circulation. 1976 Apr;53(4):728–731. doi: 10.1161/01.cir.53.4.728. [DOI] [PubMed] [Google Scholar]
  9. Peckham G. J., Miettinen O. S., Ellison R. C., Kraybill E. N., Gersony W. M., Zierler S., Nadas A. S. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. J Pediatr. 1984 Aug;105(2):285–291. doi: 10.1016/s0022-3476(84)80134-1. [DOI] [PubMed] [Google Scholar]
  10. Rennie J. M., Doyle J., Cooke R. W. Early administration of indomethacin to preterm infants. Arch Dis Child. 1986 Mar;61(3):233–238. doi: 10.1136/adc.61.3.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Silove E. D., Coe J. Y., Shiu M. F., Brunt J. D., Page A. J., Singh S. P., Mitchell M. D. Oral prostaglandin E2 in ductus-dependent pulmonary circulation. Circulation. 1981 Mar;63(3):682–688. doi: 10.1161/01.cir.63.3.682. [DOI] [PubMed] [Google Scholar]
  12. Silove E. D., Roberts D. G., de Giovanni J. V. Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease. Arch Dis Child. 1985 Nov;60(11):1025–1030. doi: 10.1136/adc.60.11.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES